IP Verse

Tert Promoter Mutations In Gliomas And A Subset Of Tumors - EP3360979

The patent EP3360979 was granted to Duke University on May 20, 2020. The application was originally filed on Feb 18, 2014 under application number EP18164632A. The patent is currently recorded with a legal status of "Revoked".

EP3360979

DUKE UNIVERSITY
Application Number
EP18164632A
Filing Date
Feb 18, 2014
Status
Revoked
Dec 9, 2022
Grant Date
May 20, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BUHLERFeb 22, 2021ADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP3360979
OPPOSITIONWO2014127359
SEARCHWO2004016813

Non-Patent Literature (NPL) Citations (68) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ADAMSON DC et al., "OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas", Cancer Res., (20100000), vol. 70, no. 1, pages 181 - 191-
DESCRIPTION- AIKATA H et al., "Telomere reduction in human liver tissues with age and chronic inflammation", Exp Cell Res., (20000000), vol. 256, no. 2, pages 578 - 582-
DESCRIPTION- AKIYAMA M et al., "Cytokines modulate telomerase activity in a human multiple myeloma cell line", Cancer Res., (20020000), vol. 62, no. 13, pages 3876 - 3882-
DESCRIPTION- ALTEKRUSE SF; MCGLYNN KA; REICHMAN ME, "Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005", J Clin Oncol., (20090000), vol. 27, no. 9, pages 1485 - 1491-
DESCRIPTION- AUBERT G; LANSDORP PM, Telomeres and aging. Physiol Rev., (20080000), vol. 88, no. 2, pages 557 - 579-
DESCRIPTION- BARANISKIN A et al., "Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma", Neuro Oncol., (20120000), vol. 14, no. 1, pages 29 - 33-
DESCRIPTION- BOLDRINI L et al., "Telomerase activity and hTERT mRNA expression in glial tumors", Int J Oncol., (20060000), vol. 28, no. 6, pages 1555 - 1560-
DESCRIPTION- BROMBERG JE; VAN DEN BENT MJ, "Oligodendrogliomas: Molecular biology and treatment", Oncologist, (20090000), vol. 14, no. 2, pages 155 - 163-
DESCRIPTION- CHARYTONOWICZ E et al., "PPARy agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma", J Clin Invest., (20120000), vol. 122, no. 3, pages 886 - 898-
DESCRIPTION- CONYERS R; YOUNG S; THOMAS DM, "Liposarcoma: Molecular genetics and therapeutics", Sarcoma, (20110000), vol. 2011, page 483154-
DESCRIPTION- COSTA A et al., "Telomere maintenance mechanisms in liposarcomas: Association with histologic subtypes and disease progression", Cancer Res., (20060000), vol. 66, no. 17, pages 8918 - 8924-
DESCRIPTION- DOLECEK TA; PROPP JM; STROUP NE; KRUCHKO C, "CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009", Neuro Oncol., (20120000), vol. 14, no. 5, pages vl - v49-
DESCRIPTION- DUNCAN CG et al., "Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes", Oncotarget, (20100000), vol. 1, no. 4, pages 265 - 277-
DESCRIPTION- FORSYTH NR; WRIGHT WE; SHAY JW, "Telomerase and differentiation in multicellular organisms: Turn it off, turn it on, and turn it off again", Differentiation, (20020000), vol. 69, no. 4-5, pages 188 - 197, XP026792136-
DESCRIPTION- GUICHARD C et al., "Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma", Nat Genet, (20120000), vol. 44, no. 6, pages 694 - 698-
DESCRIPTION- GUI Y et al., "Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder", Nat Genet, (20110000), vol. 43, no. 9, pages 875 - 878-
DESCRIPTION- HEAPHY CM et al., "Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes", Am J Pathol., (20110000), vol. 179, no. 4, pages 1608 - 1615-
DESCRIPTION- JIAO Y et al., "Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas", Oncotarget, (20120000), vol. 3, no. 7, pages 709 - 722, XP055400595-
DESCRIPTION- KANG SS; KWON T; KWON DY; DO SI, "Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit", J Biol Chem., (19990000), vol. 274, no. 19, pages 13085 - 13090-
DESCRIPTION- KOOL M et al., "Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features", PLoS One, (20080000), vol. 3, no. 8, page e3088-
DESCRIPTION- LI H; ZHAO L; YANG Z; FUNDER JW; LIU JP, "Telomerase is controlled by protein kinase Calpha in human breast cancer cells", J Biol Chem., (19980000), vol. 273, no. 50, pages 33436 - 33442-
DESCRIPTION- LI M et al., "Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma", Nat Genet, (20110000), vol. 43, no. 9, pages 828 - 829-
DESCRIPTION- LIU X et al., "HPV E6 protein interacts physically and functionally with the cellular telomerase complex", Proc Natl Acad Sci USA., (20090000), vol. 106, no. 44, pages 18780 - 18785-
DESCRIPTION- MORRISON SJ; PROWSE KR; HO P; WEISSMAN IL, "Telomerase activity in hematopoietic cells is associated with self-renewal potential", Immunity, (19960000), vol. 5, no. 3, pages 207 - 216-
DESCRIPTION- NORTHCOTT PA et al., "Medulloblastoma comprises four distinct molecular variants", J Clin Oncol., (20110000), vol. 29, no. 11, pages 1408 - 1414-
DESCRIPTION- SIEGEL R; NAISHADHAM D; JEMAL A, "Cancer statistics, 2013", CA Cancer J Clin., (20130000), vol. 63, no. 1, pages 11 - 30-
DESCRIPTION- SINGAL AG et al., "Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C Trial: Where did surveillance fail?", Am J Gastroenterol., (20120000), vol. 108, no. 3, pages 425 - 432-
DESCRIPTION- SPALDING KL; BHARDWAJ RD; BUCHHOLZ BA; DRUID H; FRISEN J, "Retrospective birth dating of cells in humans", Cell, (20050000), vol. 122, no. 1, pages 133 - 143-
DESCRIPTION- CHENG et al., "Bladder cancer: Translating molecular genetic insights into clinical practice", Hum Pathol., (20110000), vol. 42, no. 4, doi:doi:10.1016/j.humpath.2010.07.007, pages 455 - 481, XP028367813
DESCRIPTION- KING ED; MATTESON J; JACOBS SC; KYPRIANOU N, "Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: Association with tumor progression", J Urol., (19960000), vol. 155, no. 1, doi:doi:10.1016/S0022-5347(01)66652-7, pages 316 - 320, XP005576815
DESCRIPTION- SHAY JW; BACCHETTI S, "A survey of telomerase activity in human cancer", Eur J Cancer, (19970000), vol. 33, no. 5, doi:doi:10.1016/S0959-8049(97)00062-2, pages 787 - 791, XP004282534
DESCRIPTION- JANSEN M; YIP S; LOUIS DN, "Molecular pathology in adult gliomas: Diagnostic, prognostic, and predictive markers", Lancet Neurol, (20100000), vol. 9, no. 7, doi:doi:10.1016/S1474-4422(10)70105-8, pages 717 - 726, XP027598947
DESCRIPTION- CESARE AJ; REDDEL RR, "Alternative lengthening of telomeres: Models, mechanisms and implications", Nat Rev Genet, (20100000), vol. 11, no. 5, doi:doi:10.1038/nrg2763, pages 319 - 330, XP055166193
DESCRIPTION- GORANSSON M et al., "The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ", Oncogene, (20090000), vol. 28, no. 2, doi:doi:10.1038/onc.2008.378, pages 270 - 278, XP055070857
DESCRIPTION- HIYAMA E; HIYAMA K, "Telomere and telomerase in stem cells", Br J Cancer, (20070000), vol. 96, no. 7, doi:doi:10.1038/sj.bjc.6603671, pages 1020 - 1024, XP055061521
DESCRIPTION- YAN H et al., "IDH1 and IDH2 mutations in gliomas", N Engl J Med., (20090000), vol. 360, no. 8, doi:doi:10.1056/NEJMoa0808710, pages 765 - 773, XP002555011
DESCRIPTION- MAINTZ D et al., "Molecular genetic evidence for subtypes of oligoastrocytomas", J Neuropathol Exp Neurol., (19970000), vol. 56, no. 10, doi:doi:10.1097/00005072-199710000-00003, pages 1098 - 1104, XP009003087
DESCRIPTION- SJOBLOM T et al., "The consensus coding sequences of human breast and colorectal cancers", Science, (20060000), vol. 314, no. 5797, doi:doi:10.1126/science.1133427, pages 268 - 274, XP055205458
DESCRIPTION- PARSONS DW et al., "An integrated genomic analysis of human glioblastoma multiforme", Science, (20080000), vol. 321, no. 5897, doi:doi:10.1126/science.1164382, pages 1807 - 1812, XP002555012
DESCRIPTION- JIAO Y et al., "DAXX/ATRX, MEN I, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors", Science, (20110000), vol. 331, no. 6021, doi:doi:10.1126/science.1200609, pages 1199 - 1203, XP055166205
DESCRIPTION- HEAPHY CM et al., "Altered telomeres in tumors with ATRX and DAXX mutations", Science, (20110000), vol. 333, no. 6041, doi:doi:10.1126/science.1207313, page 425, XP055140966
DESCRIPTION- BETTEGOWDA C et al., "Mutations in CIC and FUBP1 contribute to human oligodendroglioma", Science, (20110000), vol. 333, no. 6048, doi:doi:10.1126/science.1210557, pages 1453 - 1455, XP055142306
DESCRIPTION- HUANG FW et al., "Highly recurrent TERT promoter mutations in human melanoma", Science, (20130000), vol. 339, no. 6122, doi:doi:10.1126/science.1229259, pages 957 - 959, XP055109644
DESCRIPTION- HORN S et al., "TERT promoter mutations in familial and sporadic melanoma", Science, (20130000), vol. 339, no. 6122, doi:doi:10.1126/science.1230062, pages 959 - 961, XP055110024
DESCRIPTION- KIM NW et al., "Specific association of human telomerase activity with immortal cells and cancer", Science, (19940000), vol. 266, no. 5193, doi:doi:10.1126/science.7605428, pages 2011 - 2015, XP002138759
DESCRIPTION- GILBERTSON RJ; ELLISON DW, "The origins of medulloblastoma subtypes", Annu Rev Pathol., (20080000), vol. 3, doi:doi:10.1146/annurev.pathmechdis.3.121806.151518, pages 341 - 365, XP009154575
EXAMINATION- BERGLIND HANNA ET AL, "Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.", CANCER BIOLOGY & THERAPY MAY 2008, (200805), vol. 7, no. 5, ISSN 1555-8576, pages 699 - 708-
EXAMINATION- GILLET JEAN-PIERRE ET AL, "The clinical relevance of cancer cell lines.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 03 APR 2013, (20130403), vol. 105, no. 7, ISSN 1460-2105, pages 452 - 458-
EXAMINATION- JIAO JINGJING ET AL, "Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors.", HEPATOLOGY COMMUNICATIONS JUN 2018, (201806), vol. 2, no. 6, ISSN 2471-254X, pages 718 - 731-
EXAMINATION- LACROIX MARC, "Persistent use of "false" cell lines.", INTERNATIONAL JOURNAL OF CANCER 01 JAN 2008, (20080101), vol. 122, no. 1, ISSN 1097-0215, pages 1 - 4-
EXAMINATION- Soussi, "HANDBOOK OF p53 MUTATION IN CELL LINES", (20070701), URL: http://p53.free.fr/Database/Cancer_cell_lines/cell_lines_1.0.pdf, (20190517), XP055589869-
EXAMINATION- Kim M. Hirshfield ET AL, "Germline Mutations and Polymorphisms in the Origins of Cancers in Women", JOURNAL OF ONCOLOGY, US, (20100101), vol. 2010, doi:10.1155/2010/297671, ISSN 1687-8450, pages 1 - 11, XP055589867
OPPOSITION- HORN, Susanne and Adina Figi, P. Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker. Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki, Dirk Schadendorf,* Rajiv Kumar, "Supplementary Materials for "TERT Promoter Mutations in Familial and Sporadic Melanoma"", sciencemag.org, (20130124), pages 1 - 30, XP055783884-
OPPOSITION- KILLELA, J., "TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal : SUPPORTING INFORMATION", (20130000), pages 1 - 5, XP055783870-
OPPOSITION- SCOTT et al., "Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma", Modern Pathology, (20130913), vol. 27, pages 516 - 523, XP055782917-
OPPOSITION- "Supplementary Table S1: TERT promoter mutations in hepatocellular carcinoma (n=305)", XP055783878-
OPPOSITION- NAULT et al., "High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions", Nature communications, (20130726), vol. 4, doi:10.1038/ncomms3218, XP055483232
OPPOSITION- KILLELA et al., "TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal", PNAS, (20130325), vol. 110, no. 15, doi:10.1073/pnas.1303607110, pages 6021 - 6026, XP055110090
OPPOSITION- HUANG F W et al, "Highly recurrent TERT Published online on promoter mutations in human melanoma", Science, (20130124), vol. 339, no. 6122, doi:10.1126/science.1229259, pages 957 - 959, XP055109644
OPPOSITION- Huang F W; Hodis E; Xu M J; Kryukov G V; Chin L; Garraway L A, "Highly Recurrent TERT Promoter Mutations in Human Melanoma (supplementary material)", (20130200), doi:10.1126/science.1229259, XP055593044
OPPOSITION- HORN et al., "TERT Promoter Mutations in Familial and Sporadic Melanoma", Science, (20130124), vol. 339, doi:10.1126/science.1230062, pages 959 - 961, XP055110024
OPPOSITION- KIM NW et al., "Specific association of human telomerase activity with immortal cells and cancer", Science, (19941223), vol. 266, doi:10.1126/science.7605428, pages 2011 - 5, XP002138759
OPPOSITION- LIU et al., "Highly prevalent TERT 12 July 2013 promoter mutations in aggressive thyroid Cancers", ; Endocrine-Related Cancer, (20130712), vol. 20, doi:10.1530/ERC-13-0210, pages 603 - 610, XP055110005
SEARCH- PARK J Y ET AL, "886 HTERT PROMOTER GENE POLYMORPHISM AND THE RISK OF HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH CHRONIC HEPATITIS B", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 52, ISSN 0168-8278, (20100401), page S345, (20100401), XP026998784 [Y] 1-15 * abstract *-
SEARCH- DANIEL HARTMANN ET AL, "Telomerase gene mutations are associated with cirrhosis formation", HEPATOLOGY, US, (20110501), vol. 53, no. 5, doi:10.1002/hep.24217, ISSN 0270-9139, pages 1608 - 1617, XP055483248 [A] 1-15 * abstract *
SEARCH- KUMI NAGAO ET AL, "Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma", JOURNAL OF GASTROENTEROLOGY, JP, (19990122), vol. 34, no. 1, doi:10.1007/s005350050220, ISSN 0944-1174, pages 83 - 87, XP055483276 [Y] 1-15 * abstract *
SEARCH- F. W. HUANG ET AL, "Highly Recurrent TERT Promoter Mutations in Human Melanoma", SCIENCE, US, (20130124), vol. 339, no. 6122, doi:10.1126/science.1229259, ISSN 0036-8075, pages 957 - 959, XP055109644 [Y] 1-15 * the whole document *
SEARCH- DENG-FU YAO, "Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma", WORLD JOURNAL OF GASTROENTEROLOGY, CN, (20060101), vol. 12, no. 31, doi:10.3748/wjg.v12.i31.4966, ISSN 1007-9327, page 4966, XP055483632 [Y] 1-15 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents